Stock Scorecard



Stock Summary for Annovis Bio Inc (ANVS) - $1.85 as of 3/28/2025 7:14:29 PM EST

Total Score

10 out of 30

Safety Score

22 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ANVS

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ANVS

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ANVS

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ANVS

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ANVS (22 out of 100)

Stock Price Rating (Max of 10) 2
Historical Stock Price Rating (Max of 10) 6
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 4
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for ANVS

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE 3/27/2025 8:30:00 PM
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program 3/25/2025 12:00:00 PM
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results 3/21/2025 9:05:00 PM
Annovis to Host Patients' Live Forum on February 27, 2025 2/19/2025 1:30:00 PM
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference 2/7/2025 1:00:00 PM
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease 2/5/2025 1:00:00 PM
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering 2/4/2025 9:31:00 PM
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering 2/3/2025 11:22:00 AM
Annovis Bio, Inc. Announces Proposed Public Offering 2/1/2025 1:14:00 AM
Annovis CEO Discusses Breakthrough Drug for Neurodegenerative Diseases on Today's Marketplace 12/4/2024 1:42:00 PM

Financial Details for ANVS

Company Overview

Ticker ANVS
Company Name Annovis Bio Inc
Country USA
Description Annovis Bio, Inc., a clinical-stage drug platform company, develops drugs to treat neurodegeneration. The company is headquartered in Berwyn, Pennsylvania.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date 5/8/2025

Stock Price History

Last Day Price 1.85
Price 4 Years Ago 17.58
Last Day Price Updated 3/28/2025 7:14:29 PM EST
Last Day Volume 167,343
Average Daily Volume 382,121
52-Week High 20.00
52-Week Low 1.52
Last Price to 52 Week Low 21.71%

Valuation Measures

Trailing PE N/A
Industry PE 37.01
Sector PE 40.10
5-Year Average PE -5.38
Free Cash Flow Ratio 2.85
Industry Free Cash Flow Ratio 11.91
Sector Free Cash Flow Ratio 47.05
Current Ratio Most Recent Quarter 2.39
Total Cash Per Share 0.65
Book Value Per Share Most Recent Quarter 0.66
Price to Book Ratio 3.87
Industry Price to Book Ratio 8.86
Sector Price to Book Ratio 21.92
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 88.85
Sector Price to Sales Ratio Twelve Trailing Months 27.78
Analyst Buy Ratings 4
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 19,486,200
Market Capitalization 36,049,470
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -122.13%
Reported EPS 12 Trailing Months -2.31
Reported EPS Past Year -2.44
Reported EPS Prior Year -6.13
Net Income Twelve Trailing Months -40,934,797
Net Income Past Year -56,200,000
Net Income Prior Year -25,300,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 12,636,630
Total Cash Past Year 5,754,720
Total Cash Prior Year 28,377,693
Net Cash Position Most Recent Quarter 12,636,630
Net Cash Position Past Year 5,754,720
Long Term Debt Past Year 0
Long Term Debt Prior Year 499,807
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 0.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year -7,750,846
Total Stockholder Equity Prior Year 28,323,530
Total Stockholder Equity Most Recent Quarter 7,063,700

Free Cash Flow

Free Cash Flow Twelve Trailing Months -22,974,234
Free Cash Flow Per Share Twelve Trailing Months -1.18
Free Cash Flow Past Year 0
Free Cash Flow Prior Year 0

Options

Put/Call Ratio 0.79
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.23
MACD Signal -0.34
20-Day Bollinger Lower Band 0.52
20-Day Bollinger Middle Band 4.15
20-Day Bollinger Upper Band 7.77
Beta 1.65
RSI 40.10
50-Day SMA 7.03
150-Day SMA 10.62
200-Day SMA 16.64

System

Modified 3/28/2025 5:33:09 PM EST